When semaglutide and tirzepatide produced weight loss results that exceeded anything previously achieved with non-surgical intervention, medicine paid attention. But as the clinical data has accumulated, researchers have recognized that these drugs are doing something far more interesting than making people less hungry.
Cardiovascular Protection
The SELECT trial — 17,604 non-diabetic, overweight adults with established cardiovascular disease — demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide compared to placebo. The effect was independent of weight loss, appearing even in patients who lost minimal weight. This is a paradigm shift: GLP-1 agonists appear to have direct cardioprotective effects through mechanisms that include reduced inflammation, improved endothelial function, and direct cardiac receptor signaling.
Kidney Protection
The FLOW trial, published in 2024, demonstrated that semaglutide reduced kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. GLP-1 receptors are expressed in kidney tissue, and direct renoprotective effects through reduced inflammation and oxidative stress have been identified in multiple studies.
Neurological Effects
GLP-1 receptors are densely expressed in the brain, particularly in regions involved in reward, cognition, and neuroinflammation. Observational data shows significantly lower rates of Alzheimer's disease and Parkinson's disease in GLP-1 agonist users compared to matched controls. Clinical trials of semaglutide for Alzheimer's disease are currently underway. The mechanism appears to involve reduced neuroinflammation, improved cerebral insulin signaling, and direct neuroprotective effects.
Addiction and Compulsive Behavior
One of the most surprising findings from GLP-1 agonist users has been spontaneous reduction in alcohol consumption, smoking, and other compulsive behaviors. This is consistent with GLP-1 receptors' role in the mesolimbic reward pathway — the brain circuit driving addiction and compulsive behavior. Research into GLP-1 agonists for alcohol use disorder and smoking cessation is actively underway.
The PepLab Protocol Integration
GLP-1 agonists are most effective when integrated with a comprehensive hormonal and metabolic evaluation — not prescribed in isolation. Muscle preservation through resistance training and protein optimization, hormonal support where deficiency exists, and monitoring of thyroid, kidney function, and body composition all maximize outcomes and minimize risks.